Q3 Cash of $5.7M Leaves Akari With Runway Only Into Q1 2027
AKTX has more than doubled off its 52-week low of $3.015 on light trading volume (0.2× avg).
Summary
Akari closed Q3 2026 with $5.7M in cash, up from $5.2M at Dec. 31, 2025, after pulling in roughly $2.9M from warrant exercises and repaying $0.7M of convertible notes, leaving none outstanding. The company's own 10-Q, filed today, carries explicit substantial doubt about its ability to continue as a going concern, with runway only into the first quarter of 2027. The planned mid-2027 Phase 1 trial for AKTX-101 is explicitly contingent on raising additional financing, so the timeline slips without a capital raise. Q3 operating expenses fell to $4.7M from $7.4M and the net loss narrowed to $4.8M from $6.4M, but the prior-year quarter included a $5.2M impairment charge, so the improvement is largely accounting-driven. GLP toxicology studies for AKTX-101 have begun, which is the one forward step here. The next hard checkpoint is financing: without new capital, the Phase 1 start does not happen.
At the time of this announcement, AKTX was trading at $6.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $3.02 to $29.32. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.